Efficiency of iguratimod combined with hydroxychloroquinein treating patients with Sjogren's syndrome and its influence on expression of surface molecules of B cells

  Objective  To analyze the clinical efficacy of hydroxychloroquine combined with iguratimod in the treatment of patients with Sjogren's syndrome and its effect on the expression of surface molecules of B cells.

  Methods  Totally 82 patients with Sjogren′s syndrome were divided into two groups, with 41 cases in each group. The control group was treated with hydroxychloroquine, while the study group was treated with hydroxychloroquine and iguratimod. The efficiency and expression of surface molecules of B cells were compared between the two groups.

  Results  The total effective rate of the study group was 90.24%, which was significantly higher than 68.29% of the control group (P < 0.05). The levels of immunoglobulin G, rheumatoid factors erythrocyte sedimentation rate and in the study group were significantly lower than those in the control group, and the platelet count was significantly higher than that in the control group (P < 0.05). The expression rates of human B-cell activating factor receptor (BAFF-R), CD38-IgD, self-perception score of Sjogren′s syndrome (ESSPRI) and disease activity of Sjogren′s syndrome (ESSDAI) score in the study group were significantly lower than those in the control group, and the value of Schirmer′s Ⅰ Test(SⅠT) and salivary flow rate were significantly higher than those in the control group (P < 0.05).

  Conclusion  Iguratimod combined with hydroxychloroquine is effective in the treatment of patients with Sjogren′s syndrome, which can inhibit the activity of B cells, prevent the accumulation of immunoglobulin and improve the symptoms of patients.